Skip to main content
Premium Trial:

Request an Annual Quote

U. of Toyoma Licenses Antibody Production Technology to MBL

NEW YORK (360Dx) — Medical & Biological Laboratories has licensed a rapid antibody production method from the University of Toyama in Japan, they announced on Tuesday.

The method called the Magnetic-beads Reaction through Arrayed Hanging-Droplets method, (MAGrahd) allows for the synthesis of an antibody gene from a single antibody-producing cell. Through the licensing agreement, MBL acquired the rights to develop and create high-performance antibodies using the MAGrahd technique worldwide.

MBL will use MAGrahd as the basis for monoclonal antibody development technologies. It will use it primarily for its diagnostic reagents business along with other technologies, such as artificial lymph node technology, phase display method, and the SPYMEG technology.

The method enables the more rapid and efficient production of target antibodies than the conventional cell fusion method, MBL and the university said, adding it shortens the time required for development projects.

Financial and other terms of the deal were not disclosed.